Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques.
Animals
Macaca fascicularis
Marburg Virus Disease
/ prevention & control
Marburgvirus
/ immunology
Viral Vaccines
/ immunology
Vesiculovirus
/ genetics
Antibodies, Viral
/ blood
Vaccines, Synthetic
/ immunology
Disease Models, Animal
Vaccination
Male
Female
Vaccine Efficacy
Genetic Vectors
Immunogenicity, Vaccine
Marburg virus
VSV
cynomolgus macaque
efficacy
filovirus
pseudotyped vector
vaccine
vesicular stomatitis virus
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
24 Jul 2024
24 Jul 2024
Historique:
received:
11
06
2024
revised:
29
06
2024
accepted:
02
07
2024
medline:
1
9
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
Filoviruses, like the Marburg (MARV) and Ebola (EBOV) viruses, have caused outbreaks associated with significant hemorrhagic morbidity and high fatality rates. Vaccines offer one of the best countermeasures for fatal infection, but to date only the EBOV vaccine has received FDA licensure. Given the limited cross protection between the EBOV vaccine and Marburg hemorrhagic fever (MHF), we analyzed the protective efficacy of a similar vaccine, rVSV-MARV, in the lethal cynomolgus macaque model. NHPs vaccinated with a single dose (as little as 1.6 × 10
Identifiants
pubmed: 39205155
pii: v16081181
doi: 10.3390/v16081181
pii:
doi:
Substances chimiques
Viral Vaccines
0
Antibodies, Viral
0
Vaccines, Synthetic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority
ID : HHSO1002019000022C